Apogee Therapeutics (APGE) Equity Ratio (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Equity Ratio data on file, last reported at 0.97 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.97, up 2.96% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.97 (up 2.96% YoY), and the FY2025 annual result was 0.96, up 1.45% from the prior year.
• Equity Ratio rose to 0.97 in Q1 2026 per APGE's latest filing, from 0.96 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.97 in Q1 2024 and troughed at 0.49 in Q2 2023.
• A 5-year average of 0.75 and a median of 0.95 in 2023 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2023 and 2025: Equity Ratio soared 506.63% in 2023, then declined 3.1% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.23 in 2022, then soared by 506.63% to 0.95 in 2023, then gained by 0.45% to 0.95 in 2024, then advanced by 1.45% to 0.96 in 2025, then gained by 0.64% to 0.97 in 2026.
• Business Quant data shows APGE's Equity Ratio at 0.97 in Q1 2026, 0.96 in Q4 2025, and 0.94 in Q3 2025.